- In April 2024, Beckman Coulter Diagnostics announced the launch of an enhanced cardiac biomarker testing panel that includes high-sensitivity myoglobin assays. This development aims to improve the early detection of acute myocardial infarction (AMI) in emergency settings by offering faster turnaround times and greater diagnostic accuracy. The panel is designed for use in high-throughput laboratories and is integrated into Beckman Coulter’s Access 2 immunoassay systems, highlighting the company's commitment to innovation in cardiac diagnostics
- In March 2024, Bio-Rad Laboratories, Inc. introduced a new range of ELISA kits for muscle physiology and cardiovascular biomarker research, including purified human and animal myoglobin assays. These products are tailored for academic and pharmaceutical research settings, enabling more precise quantification of myoglobin in complex biological samples. This launch reflects Bio-Rad’s efforts to support evolving biomedical research needs with highly specific, reproducible testing solutions
- In February 2024, Creative Diagnostics expanded its myoglobin product portfolio by introducing rapid diagnostic test strips and monoclonal antibodies for myoglobin detection. The new offerings are intended to serve both clinical diagnostics and food safety testing markets. By enhancing the accessibility of myoglobin testing across multiple sectors, Creative Diagnostics is reinforcing its role in promoting efficient, multi-purpose diagnostic tools
- In January 2024, Roche Diagnostics announced its ongoing collaboration with academic institutions in Europe to evaluate the performance of its next-generation cardiac biomarker analyzer, which incorporates myoglobin testing. The initiative is focused on optimizing early diagnosis of heart-related events in emergency care settings through improved assay precision. This partnership underscores Roche’s continued emphasis on research-driven advancements in cardiovascular diagnostics
- In December 2023, Merck KGaA's life science division introduced a new line of high-purity myoglobin reference standards for laboratory research and quality control. These products are intended to support researchers working on oxidative stress, muscle metabolism, and cardiac event modeling. Merck’s introduction of these certified reference materials illustrates its commitment to enabling scientific accuracy and reliability across diagnostic and academic laboratories
